Thailand's Department of Disease Control is tracking an evolving trio of Omicron descendants—PQ.16.1.1, RF.5, and several related sub-lineages—that are driving scattered COVID-19 surges across Asia, including a notable uptick in mainland China and Hong Kong. While these variants demonstrate enhanced immune evasion, health authorities stress there is no evidence they cause more severe illness than earlier strains, and Thailand's surveillance infrastructure remains capable of managing current case loads.
Why This Matters
• NB.1.8.1 (parent of PQ.16.1.1) accounts for 51% of sequenced samples in Thailand between January and April 2026.
• PQ.16.1.1 is fueling rapid case growth in China and Hong Kong, with increased reinfection risk despite widespread immunity.
• RF.5 has been detected in India and Singapore, exhibiting antibody resistance but no heightened severity.
• Long COVID research identifies a calcium signaling defect in immune cells, with low-dose naltrexone showing promise in restoring function.
Variant Landscape: What's Circulating Now
Genomic surveillance across Asia-Pacific reveals a fragmented picture. PQ.16.1.1, a descendant of the globally dominant NB.1.8.1 lineage, has become the most prevalent strain in Hong Kong as of July 2026, representing a majority share among severe cases, deaths, and mild infections alike. Mainland China has reported a sharp rise in infections linked to this variant throughout June, with transmission accelerating across Southeast Asia.
The RF.5 sub-lineage, a recombinant Omicron variant, has surfaced in Andhra Pradesh, India, and Singapore. The World Health Organization is monitoring RF.5 as part of its active surveillance program, noting its capacity to evade certain neutralizing antibodies—a characteristic that allows it to infect individuals with prior immunity from vaccination or previous infection. Crucially, experts emphasize that immune evasion should not be conflated with complete immune escape; existing immunity still provides substantial protection against severe outcomes.
A third designation, PJ.2.1, was referenced in limited surveillance reports but has not been confirmed in mainstream epidemiological databases. It may represent an emerging or regionally isolated lineage not yet widely characterized.
Thailand's Surveillance Infrastructure Holds Steady
Thailand's Ministry of Public Health operates a digital respiratory disease surveillance network spanning 26 sentinel hospitals nationwide. Data collected between January and late April 2026 show that NB.1.8.1 remains the dominant variant, followed by JN.1 at 25% and the recombinant XEC lineage at 9%. Earlier in the year, the XFG variant (dubbed "Stratus" internationally) held sway, but NB.1.8.1 overtook it by mid-2026.
Despite periodic seasonal increases, overall case numbers remain below the five-year median. The majority of patients present with symptoms resembling a bad cold: fever, cough, sore throat, and runny nose. Severe illness continues to concentrate among the elderly, individuals with comorbidities, and the immunocompromised—groups for whom Thailand's Department of Disease Control urges continued vigilance and adherence to basic preventive measures.
What This Means for Residents
For most people living in Thailand, these variants pose a manageable risk. The broad population retains baseline immunity from previous infections and vaccination campaigns, translating to milder illness for the majority. However, reinfection risk has increased with PQ.16.1.1 and RF.5, meaning individuals who contracted COVID-19 in 2025 may be susceptible again.
Key protective actions remain straightforward: mask-wearing in crowded indoor spaces, updated booster doses for high-risk groups, and prompt testing if symptoms develop. The Thailand Royal Police and provincial health offices have not issued movement restrictions, and tourism infrastructure remains fully operational.
Healthcare capacity is stable. Hospitals across Bangkok, Chiang Mai, and Phuket report adequate ICU availability, and antiviral treatments like Paxlovid remain accessible through government health facilities and private clinics.
Global Context: Regional Variation in Surge Patterns
While Thailand's case numbers remain moderate, neighboring territories are experiencing sharper climbs. China, Taiwan, Japan, South Korea, and Singapore all reported rising activity in June, driven largely by NB.1.8.1 and its sub-lineages. Conversely, the United States, Canada, and most of Europe continue to register low COVID-19 activity, with predictions for a mild summer surge and a more significant winter wave.
The World Health Organization designated NB.1.8.1 ("Nimbus"), XFG ("Stratus"), and BA.3.2 ("Cicada") as variants under monitoring as of June 21, 2026. NB.1.8.1 accounted for 50% of all sequences submitted globally that week, cementing its status as the most widespread lineage. BA.3.2 is rapidly expanding in Japan, South Korea, and parts of Europe, though it has not yet gained traction in Southeast Asia.
Long COVID: A Calcium Signaling Puzzle
Parallel to variant surveillance, researchers have made significant strides in understanding Long COVID, the persistent syndrome affecting millions worldwide. Studies published in 2024 and 2025 identified a disruption in TRPM3 ion channels within natural killer (NK) cells—a type of immune cell critical for antiviral defense. This dysfunction impairs calcium influx, weakening cellular processes and contributing to the fatigue, cognitive impairment, and other symptoms characteristic of Long COVID.
Naltrexone hydrochloride (NTX) and low-dose naltrexone (LDN) have shown promise in clinical trials. Research published in May 2024 demonstrated that in vitro treatment with NTX restored TRPM3 function in NK cells from post-COVID patients. A follow-up study in May 2025 confirmed that Long COVID patients treated with LDN experienced restored ion channel activity, validating the therapeutic potential of this widely available, low-cost medication.
While not a cure, these findings represent a tangible treatment avenue for Long COVID sufferers in Thailand. LDN is available at major hospitals and specialty clinics, though it is not yet part of standard COVID-19 treatment protocols. Patients experiencing persistent symptoms may consult with infectious disease specialists or immunologists to explore this option.
Severity vs. Transmissibility: The Reassuring Picture
Despite the proliferation of sub-lineages, no current variant has demonstrated increased lethality compared to earlier Omicron waves. Symptoms associated with PQ.16.1.1, RF.5, and related strains mirror those of previous Omicron infections: sore throat, dry cough, congestion, headache, fatigue, and body aches. Fever is common but typically resolves within three to five days.
Hospitalizations remain concentrated among unvaccinated individuals and those with pre-existing conditions. Vaccines deployed in Thailand—including updated formulations targeting JN.1 and its descendants—continue to provide robust protection against severe disease and death, even when breakthrough infections occur.
Practical Takeaways
The evolving variant landscape does not necessitate panic, but it does require informed vigilance. Residents should:
• Monitor symptoms closely, especially after travel to China, Hong Kong, or Singapore.
• Consider booster vaccination if more than six months have elapsed since the last dose, particularly for individuals over 60 or with chronic illness.
• Maintain basic hygiene practices: handwashing, avoiding crowded spaces when symptomatic, and wearing masks in high-risk settings like hospitals or public transport.
• Consult healthcare providers promptly if symptoms worsen or persist beyond a week, as early antiviral treatment remains most effective within the first five days of infection.
For those experiencing Long COVID, low-dose naltrexone represents a research-backed intervention worth discussing with a physician. While not universally effective, the TRPM3 calcium signaling mechanism offers a biological rationale that distinguishes it from anecdotal remedies.
Forward Outlook
Thailand's Department of Disease Control has pledged continued genomic surveillance and real-time reporting through its 26-hospital sentinel network. Seasonal waves are expected through late 2026, with a potential uptick during the cooler months between November and January. However, the combination of widespread immunity, functional healthcare infrastructure, and moderate variant severity suggests that Thailand remains well-positioned to manage COVID-19 as an endemic respiratory illness rather than a crisis-level threat.
The global pattern—regional surges followed by stabilization—reinforces the importance of localized preparedness over blanket restrictions. For residents, the message is clear: stay informed, maintain basic precautions, and seek care when needed. The virus continues to evolve, but so too does our capacity to respond.
